| Recruiting | Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Pati NCT07141407 | Fred Hutchinson Cancer Center | N/A |
| Not Yet Recruiting | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tum NCT07405086 | OHSU Knight Cancer Institute | Phase 2 |
| Not Yet Recruiting | Adoption of Audio Recording in the Outpatient Supportive Care Center NCT04871477 | M.D. Anderson Cancer Center | — |
| Recruiting | TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, NCT07189195 | University of California, Davis | Phase 1 |
| Recruiting | Educational Tools for the Improvement of Early Advance Care Planning in Adolescents and Young Adults With Adva NCT07174661 | Mayo Clinic | N/A |
| Active Not Recruiting | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Brea NCT06630325 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Studying TAK-243 in Patients With Advanced Cancer NCT06223542 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or NCT06311214 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients NCT06834386 | Mayo Clinic | Phase 4 |
| Enrolling By Invitation | Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients With Serious I NCT06630351 | Mayo Clinic | N/A |
| Recruiting | Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumo NCT05638295 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors NCT05653661 | Mayo Clinic | Phase 1 |
| Recruiting | Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, He NCT05705492 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Recha NCT06470971 | Yuanquan Yang | Phase 2 |
| Recruiting | Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers NCT05691517 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid NCT05687136 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Meta NCT06320405 | OHSU Knight Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inh NCT06438588 | Mayo Clinic | N/A |
| Recruiting | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effective NCT05691491 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer NCT05969860 | Mayo Clinic | Phase 2 |
| Recruiting | The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor C NCT05967533 | University of California, Davis | Phase 1 |
| Recruiting | Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunot NCT05039632 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo NCT05564377 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease NCT05791448 | University of Southern California | Phase 1 |
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Recruiting | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors NCT05053971 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advance NCT05327010 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment NCT05455606 | SWOG Cancer Research Network | N/A |
| Suspended | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic NCT05111561 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer NCT05403580 | Mayo Clinic | Phase 3 |
| Withdrawn | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ an NCT06400264 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors NCT05038839 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients NCT04939090 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of NCT05101356 | Tianhong Li | Phase 1 / Phase 2 |
| Recruiting | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors NCT05039801 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or C NCT04491942 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tu NCT04704661 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Car NCT04090619 | M.D. Anderson Cancer Center | — |
| Recruiting | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Color NCT04511039 | Roswell Park Cancer Institute | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea NCT04616534 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Distress Associated with Coronavirus Disease 2019 and Telehealth on Supportive Care Patients with Advanced Can NCT05058339 | M.D. Anderson Cancer Center | — |
| Terminated | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progress NCT04902040 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metasta NCT04785287 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers NCT04870788 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Learning Collaborative Versus Technical Assistance in Delivering a Palliative Care Program to Patients With Ad NCT04062552 | University of Rochester NCORP Research Base | N/A |
| Recruiting | A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648 | RasCal Therapeutics, Inc. | Phase 1 |
| Terminated | SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTI NCT04729725 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer NCT04697524 | University of California, San Francisco | N/A |
| Active Not Recruiting | Patient Considerations of Social Media Account Management After Death NCT05035667 | M.D. Anderson Cancer Center | — |
| Recruiting | Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, NCT04693468 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study NCT04552704 | Tianhong Li | Phase 1 / Phase 2 |
| Withdrawn | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumor NCT03925428 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer NCT04294628 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their NCT04984551 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Technology-Enhanced Palliative Care for Advanced Cancer Patients NCT04989556 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without NCT04317105 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Pati NCT04197713 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers NCT04171219 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations NCT04233567 | Sameek Roychowdhury | Phase 2 |
| Active Not Recruiting | Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydroch NCT03872427 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients W NCT03842228 | National Cancer Institute (NCI) | Phase 1 |
| Completed | BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients NCT04021043 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol NCT06400251 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors NCT03784677 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Sub NCT06400225 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer NCT03927885 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Completed | SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies NCT03831295 | Ronald Levy | Phase 1 |
| Active Not Recruiting | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage S NCT03830918 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors NCT03756818 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Muta NCT03212274 | National Cancer Institute (NCI) | Phase 2 |
| Completed | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors NCT03725436 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification NCT03253679 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H NCT06400238 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MAT NCT06308822 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Ad NCT03583255 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) NCT05490771 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | FID-007 in Treating Participants With Advanced Solid Tumors NCT03537690 | University of Southern California | Phase 1 |
| Withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers NCT03017833 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A NCT06385483 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors NCT03237390 | Mayo Clinic | Phase 1 |
| Completed | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03213678 | National Cancer Institute (NCI) | Phase 2 |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213665 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or NCT03065387 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lympho NCT03213691 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced NCT03217747 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY NCT02650986 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification NCT06390839 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) NCT04439227 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATC NCT06390865 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subp NCT06385496 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z NCT06390852 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue i NCT03035409 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol NCT06390826 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by S NCT02503709 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors NCT02498613 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic NCT02721732 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol NCT06357975 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MAT NCT06360575 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) NCT04439240 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol NCT04439344 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subproto NCT04439214 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification ( NCT04439201 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) NCT04439123 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N NCT04439149 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotoco NCT04439188 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelio NCT02535312 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1 NCT04439318 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subp NCT04439357 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-S NCT04439175 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) NCT04439305 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant NCT06357988 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) NCT06303167 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subp NCT04439331 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Can NCT02451553 | University of Washington | Phase 1 |
| Terminated | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lym NCT02408861 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Sol NCT02389309 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for NCT02317874 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) NCT04439136 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATC NCT04439110 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) NCT04439266 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R NCT04439279 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G NCT04439253 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATC NCT04439292 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors NCT01591356 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherap NCT02419495 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or NCT02227940 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients NCT02152943 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Canno NCT02159989 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction NCT02070549 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations NCT01827384 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus NCT01822522 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ipilimumab and Imatinib Mesylate in Advanced Cancer NCT01738139 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors NCT01628640 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostat NCT01480154 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors NCT01434316 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma NCT01303341 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Remove NCT00576654 | National Cancer Institute (NCI) | Phase 1 |